WO2003089457A3 - Peptide inhibitors of protein kinase c ϝ for pain management - Google Patents

Peptide inhibitors of protein kinase c ϝ for pain management Download PDF

Info

Publication number
WO2003089457A3
WO2003089457A3 PCT/US2003/012542 US0312542W WO03089457A3 WO 2003089457 A3 WO2003089457 A3 WO 2003089457A3 US 0312542 W US0312542 W US 0312542W WO 03089457 A3 WO03089457 A3 WO 03089457A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
pain management
peptide inhibitors
pain
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/012542
Other languages
French (fr)
Other versions
WO2003089457B1 (en
WO2003089457A2 (en
Inventor
Daria Mochly-Rosen
Sarah M Sweitzer
Joan J Kendig
David C Yeomans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to JP2003586177A priority Critical patent/JP2005527209A/en
Priority to EP03728495A priority patent/EP1501533A4/en
Priority to AU2003234186A priority patent/AU2003234186B2/en
Priority to CA2481512A priority patent/CA2481512C/en
Publication of WO2003089457A2 publication Critical patent/WO2003089457A2/en
Publication of WO2003089457A3 publication Critical patent/WO2003089457A3/en
Publication of WO2003089457B1 publication Critical patent/WO2003089457B1/en
Anticipated expiration legal-status Critical
Priority to AU2009201593A priority patent/AU2009201593B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)

Abstract

Peptide sequences derived from the V5 domain of isozymes of protein kinase C for use in pain management are described. Also described are compositions comprising the peptides for treating pain and/or inducing analgesia. Methods of pain treatment and methods of identifying compounds that mimic the activity of the peptides are also described.
PCT/US2003/012542 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c ϝ for pain management Ceased WO2003089457A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003586177A JP2005527209A (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase Cγ for pain management
EP03728495A EP1501533A4 (en) 2002-04-22 2003-04-22 PEPTIDE INHIBITORS OF PROTEIN KINASE C-GAMMA FOR THE MANAGEMENT OF PAIN
AU2003234186A AU2003234186B2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C Gamma for pain management
CA2481512A CA2481512C (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c.gamma. for pain management
AU2009201593A AU2009201593B2 (en) 2002-04-22 2009-04-22 Peptide inhibitors of protein kinase C y for pain management

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37453002P 2002-04-22 2002-04-22
US60/374,530 2002-04-22

Publications (3)

Publication Number Publication Date
WO2003089457A2 WO2003089457A2 (en) 2003-10-30
WO2003089457A3 true WO2003089457A3 (en) 2004-01-22
WO2003089457B1 WO2003089457B1 (en) 2004-04-15

Family

ID=29251202

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/012542 Ceased WO2003089457A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c ϝ for pain management
PCT/US2003/012541 Ceased WO2003089456A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/012541 Ceased WO2003089456A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c

Country Status (6)

Country Link
US (8) US7393835B2 (en)
EP (3) EP1501533A4 (en)
JP (5) JP2005527209A (en)
AU (4) AU2003234186B2 (en)
CA (3) CA2481512C (en)
WO (2) WO2003089457A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376423B2 (en) 2010-08-10 2016-06-28 The Regents Of The University Of California PKC-epsilon inhibitors

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
AU2003241559A1 (en) * 2003-05-16 2004-12-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
AU2003264918A1 (en) * 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) * 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
EP1699813A2 (en) * 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US20100041597A1 (en) 2005-08-05 2010-02-18 Jenny Phipps Peptides targeted to protein kinase c isoforms and uses thereof
WO2007025286A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
CA2644089A1 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US20100279944A1 (en) * 2006-03-30 2010-11-04 Ronald Mathison Suppression and treatment of neuropathic pain
WO2007143119A2 (en) * 2006-06-01 2007-12-13 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing progression of hypertension-induced heart failure with pkc peptides
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8017583B2 (en) 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
EP2144615A4 (en) * 2007-04-06 2011-02-16 Kai Pharmaceuticals Inc Methods of use of gamma inhibitor compounds for the attenuation of pain
WO2008154004A2 (en) * 2007-06-07 2008-12-18 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
ES2703571T3 (en) * 2008-03-27 2019-03-11 Nestec Sa Methods to increase the absorption of peptides, peptidomimetics and other substrates of gastrointestinal transport protein
WO2010019965A1 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CN102388130B (en) 2009-02-27 2014-08-27 细胞动力国际有限公司 Differentiation of pluripotent cells
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
EP2482837A4 (en) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc USE OF INHIBITORS OF PROTEIN KINASE C DELTA (PKCD) FOR THE TREATMENT OF DIABETES, OBESITY AND HEPATIC STEATOSIS
WO2011109678A1 (en) * 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
WO2013025525A1 (en) 2011-08-12 2013-02-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
JP6998657B2 (en) 2013-09-18 2022-02-04 エピアクシス セラピューティクス プロプライエタリー リミテッド Stem cell regulation II
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
MX2018012351A (en) 2016-04-12 2019-02-07 Trigemina Inc OXITOCINE FORMULATIONS CONTAINING MAGNESIUM AND METHODS OF USE.
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest SYNTHASE ATP modulators treatments of the opposite state of
CA3082055A1 (en) 2017-11-08 2019-05-16 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor
US20230003894A1 (en) * 2019-12-16 2023-01-05 Sony Semiconductor Solutions Corporation Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method
JP7649479B2 (en) * 2020-03-31 2025-03-21 東レ株式会社 Image analysis device, control method for image analysis device, image analysis system, and control method for image analysis system
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351829A (en) 1980-09-26 1982-09-28 Farmitalia Carlo Erba Spa Use of polypeptides as analgesic drugs
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6218113B1 (en) 1998-02-24 2001-04-17 Incyte Genomics, Inc. Human protein kinase C inhibitor
DE69934689T2 (en) 1998-07-06 2007-10-25 The Regents Of The University Of California, Oakland USE OF PROTEIN KINASE C EPSILON INHIBITORS FOR THE TREATMENT OF PAIN
DE69920473T2 (en) * 1998-07-21 2006-02-23 Cytovia, Inc., San Diego NEW FLUORESCENCE DYES AND THEIR APPLICATION IN FLUORESCENCE DETECTION METHODS OF FULL CELLS FOR CASAS, PEPTIDASES, PROTEASES AND OTHER ENZYMES AND THEIR USE
US6395306B1 (en) * 1998-09-14 2002-05-28 Pan Pacific Pharmaceuticals, Inc. Bee venom protein and gene encoding same
JP2002525382A (en) * 1998-09-25 2002-08-13 ザ チルドレンズ メディカル センター コーポレイション Short peptide that selectively regulates protein kinase activity
GB9905218D0 (en) 1999-03-09 1999-04-28 Univ Glasgow Neurodegenerative disorder related gene
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
CN1300845A (en) 1999-12-22 2001-06-27 上海博德基因开发有限公司 Polypeptide-human diaoylglycerol protein kinase subunit 9 and polynucleotide for coding this polypeptide
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6496425B1 (en) * 2000-08-21 2002-12-17 Micron Technology, Inc Multiple bit line column redundancy
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1501533A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376423B2 (en) 2010-08-10 2016-06-28 The Regents Of The University Of California PKC-epsilon inhibitors

Also Published As

Publication number Publication date
AU2003234186B2 (en) 2009-01-22
CA2785889A1 (en) 2003-10-30
AU2009201593A1 (en) 2009-05-21
US7459424B2 (en) 2008-12-02
EP1501532A2 (en) 2005-02-02
JP2009091372A (en) 2009-04-30
US20090143293A1 (en) 2009-06-04
US7393835B2 (en) 2008-07-01
US9365837B2 (en) 2016-06-14
JP2005523326A (en) 2005-08-04
EP1501532A4 (en) 2007-11-14
JP2012176978A (en) 2012-09-13
AU2003234186A1 (en) 2003-11-03
AU2003234185B2 (en) 2009-02-05
AU2009201760A1 (en) 2009-05-28
CA2481512C (en) 2013-06-18
US20080167247A1 (en) 2008-07-10
US20030223981A1 (en) 2003-12-04
US20140178352A1 (en) 2014-06-26
CA2482598A1 (en) 2003-10-30
AU2003234185C1 (en) 2009-11-19
WO2003089456A2 (en) 2003-10-30
US20050215483A1 (en) 2005-09-29
WO2003089456A3 (en) 2004-02-12
CA2481512A1 (en) 2003-10-30
EP2332559A1 (en) 2011-06-15
WO2003089457B1 (en) 2004-04-15
US20110275575A1 (en) 2011-11-10
AU2009201760B2 (en) 2011-03-17
JP2009102392A (en) 2009-05-14
US7833984B2 (en) 2010-11-16
CA2482598C (en) 2012-09-25
AU2003234185A1 (en) 2003-11-03
EP1501533A4 (en) 2007-10-31
JP2005527209A (en) 2005-09-15
US20040009922A1 (en) 2004-01-15
US8658594B2 (en) 2014-02-25
US7939493B2 (en) 2011-05-10
AU2009201593B2 (en) 2012-05-24
WO2003089457A2 (en) 2003-10-30
US20090192091A1 (en) 2009-07-30
EP1501533A2 (en) 2005-02-02
US7507711B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
DE69910368D1 (en) PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUALFUNCTIONAL DISORDERS
DE69828408D1 (en) NAPHTHYRIDINONE FOR INHIBITING THE CELL REPRODUCTION THROUGH PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE
ATE527022T1 (en) USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT AND PREVENTION OF TUMORS, TUMOR-DEPENDENT DISEASES AND CACHEXIA
ATE326239T1 (en) METHODS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE IN SUCH METHODS
MXPA05005398A (en) Target for therapy of cognitive impairment.
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
DE69805973D1 (en) TREATING HEART CRYSTAL DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM / CALMODULIN-DEPENDENT PROTEIN KINASE
NZ607892A (en) Tfpi inhibitors and methods of use
MY169308A (en) Treatment of tnf? related disorders
DE60141230D1 (en) Use of botulinum toxin for the treatment of neuralgic pain
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
EP1426768A3 (en) Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
AU2003211009A8 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
EP1499190A4 (en) METHOD FOR THE TREATMENT OF ILL. DISEASES AND LIVER DAMAGES WITH GROWTH HORMONE AND FOXM1B
ATE173620T1 (en) USE OF AN ANTAGONIST OF TNF-ALPHA FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
IL149416A0 (en) Human enzymes of the metalloprotease family
ATE313561T1 (en) VGF POLYPEPTIDES AND METHODS FOR TREATING VGF DISEASES
ATE526056T1 (en) IGF-2 PEPTIDE FOR USE IN TOLEROGENIC TREATMENT FOR TYPE I DIABETES
DE60137721D1 (en) INHIBITORS OF LYN-ASSOCIATED SIGNAL TRANSDUCTION (LOAD) AND THEIR USE FOR THE TREATMENT OF PROSTATE CANCER
IL139144A0 (en) Mycobacterial inhibitors
ID23184A (en) SALES OF BPC PEPTIDES WITH ORGANOPROTECTIVE ACTIVITIES FOR THE PROCESS OF MAKING AND USING IT IN THERAPY
DE50308460D1 (en) USE OF AMBROXOL FOR THE TREATMENT OF CHRONIC PAIN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20031230

WWE Wipo information: entry into national phase

Ref document number: 2003234186

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2481512

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003586177

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003728495

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003728495

Country of ref document: EP